College of Life Sciences, Nanjing Normal University, No. 1 Wenyuan Road, Nanjing, 210023, Jiangsu, PR China.
Department of Colorectal Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, No. 155 Hanzhong Road, Nanjing, 210029, Jiangsu, PR China.
J Exp Clin Cancer Res. 2022 Jun 11;41(1):198. doi: 10.1186/s13046-022-02412-3.
NCAPD3 is one of the three non-SMC subunits of condensin II complex, which plays an important role in the chromosome condensation and segregation during mitosis. Notably, elevated levels of NCAPD3 are found in many somatic cancers. However, the clinical role, biological functions of NCAPD3 in cancers especially in colorectal cancer (CRC) and the underlying molecular mechanisms remain poorly elucidated.
Clinical CRC and adjacent normal tissues were used to confirm the expression of NCAPD3. The association of NCAPD3 expression with clinicopathological characteristics and patient outcomes were analyzed by using online database. In vivo subcutaneous tumor xenograft model, NCAPD3 gene knockout following azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced tumor mouse model, Co-IP, western blot, qRT-PCR, IHC, ChIP assays and cell functional assays were used to investigate the biological functions of NCAPD3 in CRC and the underlying molecular mechanisms.
NCAPD3 was overexpressed in CRC tissues and positively correlated with poor prognosis of CRC patients. NCAPD3 knockout suppressed CRC development in AOM/DSS induced and xenograft mice models. Moreover, we found that NCAPD3 promoted aerobic glycolysis in CRC. Mechanistically, NCAPD3 up-regulated the level of c-Myc and interacted with c-Myc to recruit more c-Myc to the gene promoter of its downstream glycolytic regulators GLUT1, HK2, ENO1, PKM2 and LDHA, and finally enhanced cellular aerobic glycolysis. Also, NCAPD3 increased the level of E2F1 and interacted with E2F1 to recruit more E2F1 to the promoter regions of PDK1 and PDK3 genes, which resulted in the inhibition of PDH activity and TCA cycle.
Our data demonstrated that NCAPD3 promoted glucose metabolism reprogramming and enhanced Warburg effect in colorectal tumorigenesis and CRC progression. These findings reveal a novel mechanism underlying NCAPD3 mediated CRC cell growth and provide new targets for CRC treatment.
NCAPD3 是凝缩素 II 复合物的三个非 SMC 亚基之一,在有丝分裂过程中染色体的浓缩和分离中发挥重要作用。值得注意的是,NCAPD3 在许多实体瘤中表达水平升高。然而,NCAPD3 在癌症中的临床作用、生物学功能,尤其是在结直肠癌(CRC)中的临床作用、生物学功能以及潜在的分子机制仍未得到充分阐明。
采用临床 CRC 及相邻正常组织验证 NCAPD3 的表达。利用在线数据库分析 NCAPD3 表达与临床病理特征和患者预后的关系。通过体内皮下肿瘤异种移植模型、AOM/DSS 诱导的肿瘤小鼠模型中 NCAPD3 基因敲除、Co-IP、western blot、qRT-PCR、IHC、ChIP 实验和细胞功能实验,研究 NCAPD3 在 CRC 中的生物学功能及其潜在的分子机制。
NCAPD3 在 CRC 组织中高表达,与 CRC 患者的不良预后呈正相关。NCAPD3 敲除抑制 AOM/DSS 诱导的 CRC 发生和异种移植小鼠模型中的肿瘤生长。此外,我们发现 NCAPD3 促进 CRC 有氧糖酵解。机制上,NCAPD3 上调 c-Myc 水平,并与 c-Myc 相互作用,募集更多的 c-Myc 到其下游糖酵解调节因子 GLUT1、HK2、ENO1、PKM2 和 LDHA 的基因启动子,最终增强细胞有氧糖酵解。此外,NCAPD3 增加 E2F1 水平,并与 E2F1 相互作用,募集更多的 E2F1 到 PDK1 和 PDK3 基因的启动子区域,导致 PDH 活性和 TCA 循环的抑制。
我们的数据表明,NCAPD3 促进了葡萄糖代谢重编程,并增强了结直肠肿瘤发生和 CRC 进展中的瓦伯格效应。这些发现揭示了 NCAPD3 介导的 CRC 细胞生长的新机制,并为 CRC 的治疗提供了新的靶点。